OrbiMed’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

OrbiMed’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-100,000	Closed	-$1.52M	–	142
2014 Q4	$1.52M	Buy	+100,000	New	+$1.21M	0.01%	124

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

OrbiMed's SGMO Position: Q1 2017 in Review

OrbiMed sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2017, closing a stake of 707,400 shares — an estimated $2.16M sold.

OrbiMed first reported a position in SGMO in Q3 2016 and held it in 2 quarters. The position peaked at $3.85M in Q3 2016. 118 funds tracked by Wall St. Rank hold SGMO as of Q1 2017.

OrbiMed reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2017 after selling out during the quarter.
OrbiMed sold 707,400 SANGAMO THERAPEUTICS INC shares in Q1 2017, an estimated $2.16M.
OrbiMed first reported a position in SANGAMO THERAPEUTICS INC in Q3 2016 and held it in 2 quarters.
OrbiMed's SANGAMO THERAPEUTICS INC position peaked at $3.85M in Q3 2016.
118 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2017.

Based on OrbiMed's 13F filing for Q1 2017, filed 15 May 2017.